NFKBIA Monoclonal Antibody

Definition and Mechanism of Action

NFKBIA (nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha) encodes a protein that inhibits NF-κB/REL complexes by masking their nuclear localization signals. This prevents their translocation into the nucleus, thereby suppressing pro-inflammatory and oncogenic transcriptional programs . Monoclonal antibodies against NFKBIA are engineered to bind specifically to its epitopes, enabling precise detection or modulation of this protein in experimental systems.

Production and Types of NFKBIA Monoclonal Antibodies

NFKBIA monoclonal antibodies are produced via hybridoma technology or recombinant methods:

• Hybridoma-derived antibodies: Immunized animals (e.g., mice) generate B cells, which are fused with myeloma cells to create hybridomas. Clones producing NFKBIA-specific antibodies are selected (e.g., ABIN1326940) .

• Recombinant antibodies: Heavy and light chain genes are cloned from hybridomas and expressed in host systems (e.g., CSB-RA015761A0HU) .

Applications in Research and Diagnostics

NFKBIA monoclonal antibodies are employed in:

• Western blotting (WB): To quantify NFKBIA protein levels (e.g., detecting a 35 kDa band in MCF7 cells) .

• Immunohistochemistry (IHC): For spatial localization in tissue samples.

• Immunoprecipitation (IP): To study protein-protein interactions involving NFKBIA.

• ELISA: To measure NFKBIA in lysates or serum.

Validation methods:

• siRNA knockdown: Antibody staining intensity decreases upon NFKBIA silencing .

• GFP-tagged cell lines: Overlap between antibody signal and GFP-tagged NFKBIA confirms specificity .

NFKBIA Haploinsufficiency in Gliomas

Deletions or mutations in NFKBIA are linked to poor prognosis in gliomas. Key findings include:

Role in Cancer and Immunology

• Tumor Suppression: NFKBIA acts as a tumor suppressor by inhibiting NF-κB-driven oncogenic pathways. Loss of NFKBIA enhances cancer cell proliferation and therapy resistance .

• Immune Regulation: Monoclonal antibodies targeting NFKBIA may modulate immune responses, with implications for autoimmune diseases or immunotherapy .

Research Challenges and Future Directions

• Epigenetic Crosstalk: The interplay between NFKBIA deletions and polycomb repressive complex 1 (PRC1) activity in gliomas requires further investigation .

• Therapeutic Potential: Engineering NFKBIA-targeted antibodies to restore its function or inhibit NF-κB signaling in cancers with NFKBIA loss.